Source comparison
Thymosin Alpha-1 Dosage Timing: Research vs Supplement Comparison
| Protocol Type | Typical Dose per Injection | Frequency | Timing Recommendation | Duration in Studies | Clinical Context | Professional Assessment ||—|—|—|—|—|—|| Published Immune Research (Hepatitis B/C) | 1.6mg subcutaneous | 2× weekly | Evening (6–10 PM) |
This comparison does not assign a generated winner or score.
- | Protocol Type | Typical Dose per Injection | Frequency | Timing Recommendation | Duration in Studies | Clinical Context | Professional Assessment ||—|—|—|—|—|—|| Published Immune Research (Hepatitis B/C) | 1.6mg subcutaneous | 2× weekly | Evening (6–10 PM) | 12–24 weeks | Immune-compromised patients with chronic viral infection | Gold standard. Aligns dose, frequency, and timing with circadian immune peaks || Cancer Immunotherapy Adjuvant | 3.2–6.4mg subcutaneous | 3× weekly | Evening preferred, not always specified | 8–16 weeks | Oncology patients receiving concurrent chemotherapy or radiation | Higher doses used in severely immunosuppressed contexts. Not appropriate for general immune support || Oral Thymosin Supplements | Varies (often unspecified or <1mg per capsule) | Daily | Any time of day | Continuous | General wellness marketing | Oral bioavailability of thymosin alpha-1 is near-zero. Peptides are degraded in the GI tract before systemic absorption || Topical/Nasal Thymosin